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ABSTRACT
A topical vehicle is a ‘carrier system’ for an active pharmaceutical (or cosmetic) substance, referred to
hereafter as the drug, but a vehicle may also be used on its own as an emollient to ameliorate dry
skin. It is well established that the vehicle plays an important role in determining the bioavailability of
a given drug at its ultimate target within the skin. Yet in the treatment of atopic eczema/dermatitis
(AD), wherein the structure and function of the skin’s outer barrier play a pivotal role in the develop-
ment and course of the condition, the interaction of the vehicle with this barrier carries a particular
importance. It is now clear that the often-considered inert excipients of a vehicle bring about changes
within the skin at the molecular level that promote barrier restoration and enhance innate immune
defenses with therapeutic value to AD patients. Moreover, the vehicle control in randomized con-
trolled trials (RCTs) increasingly displays significant efficacy. In light of this, we consider the implica-
tions of vehicle design in relation to AD pathophysiology and the role vehicles play as controls in
RCTs of new drug treatments for this condition.
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Atopic dermatitis and the skin barrier
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory dis-
ease of the skin, which is characterized by xerosis, pruritus, and
erythematous lesions. The prevalence of AD is high, affecting
15% to 30% of children and 2% to 10% of adults (1). It is a dis-
ease that can cause enormous suffering at a crucial time in a
child’s development (2). A key event in the development of AD
is breakdown of the skin barrier, formed by the intact stratum
corneum (SC) (3). Skin barrier breakdown in AD can also occur
as a result of the pro-allergic inflammatory state, characterized
by high levels of T-helper type 2 (Th2) cytokines including inter-
leukin (IL)-4 and IL-13 (4).
The structure of the skin barrier is often compared to that of
a brick wall (Figure 1). The bricks represent the corneocytes,
which are terminally differentiated keratinocyte cells. The mortar
around the brick represents the lipid lamellae, a highly ordered
arrangement of lipids that restricts water movements between
the corneocytes (5). The functional integrity of these lipids, as a
barrier to water, is dependent on the balance between the
three constituent lipid types: ceramides, fatty acids and choles-
terol. The corneocytes, which are themselves coated in an insol-
uble layer of protein (water-proofing), harbor a collection of
water binding molecules (humectants) referred to as natural
moisturizing factor (NMF). NMF accounts for 20% to 30% of the
SC by weight, and helps keep the skin hydrated (6). Together
this two-compartment system (bricks and mortar) creates an
effective permeability barrier. This barrier provides essential pro-
tection from dehydration (inside-outside water permeation) and
from irritants and allergens in the environment (outside-inside
permeation) (3).
The skin barrier of patients with AD is defective, allowing
water to escape, and predisposing the skin to dryness (7). The
defect arises due to abnormalities affecting both the bricks and
the mortar. Broadly, altered differentiation of keratinocytes cul-
minates in an abnormal formation of the insoluble protein layer
around the corneocytes and reduced production of NMF con-
tained within them. This reduces the skin’s capacity to retain
moisture (6). Broad defects in lipid production, trafficking and
processing culminates in a similarly defective lipid matrix
around the corneocytes (5). This increases the permeability of
the SC to water.
Disruption of the skin barrier triggers an abnormal response
in patients with AD that favors pro-allergic inflammation (8).
Innate defense mechanisms, such as the production of anti-
microbial peptides and skin barrier repair mechanisms are inhib-
ited under these conditions (9). The microbiome on the skin
changes, and the opportunistic pathogen Staphylococcus aureus
frequently takes hold, which can subsequently aggravate the
inflammatory response (10,11). Damage to the skin barrier per-
mits the penetration of irritants and allergens, which subse-
quently triggers immune system hyper-reactivity. In this way the
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structure and function of the skin barrier plays a pivotal role in
both the development and fluctuating persistence of AD (3).
The role of vehicles
The role of the vehicle is to sustainably deliver the active
pharmaceutical substance (i.e. drug) to the target site within the
skin at an appropriate level to provide a pharmacological
effect (12,13).
Currently, the most commonly used topically delivered
pharmaceutical drugs for the treatment of AD are corticoste-
roids (14). Topical corticosteroids (TCSs) exhibit broad anti-
inflammatory effects that have proven effective in suppressing
inflammatory lesions of AD. To exert a pharmacological effect,
corticosteroids must reach the viable epidermis and dermis
where they target the glucocorticoid receptor (GR) expressed by
infiltrating immune cells, keratinocytes and fibroblasts. There are
several technically challenging barriers that stand between the
active drug within the vehicle and the target site (Figure 1) (15).
To overcome these barriers a vehicle must:
1. maintain the solubility and stability of the active drug;
2. release the active drug, depositing it on the skin with even
distribution;
3. enable penetration into and permeation through the SC/
skin barrier;
4. facilitate partitioning from the SC into and diffusion
through the viable epidermis;
5. sustain the active drug at the target site for a sufficient
duration to provide a pharmacologic effect; and
6. limit systemic absorption.
Drug delivery
The rate-limiting step in topical drug delivery is often partition-
ing into and permeation across the SC, which forms the skin
barrier. From a drug delivery perspective, the SC can be seen as
a two-compartment structure of hydrophilic cells (bricks) within
a hydrophobic matrix (mortar). Inevitably this highly effective
natural barrier creates a significant obstacle for the delivery of
active drugs. To permeate through the SC (transdermal delivery)
a drug must take 1 of 2 direct paths: (1) the intercellular path
through the continuous hydrophobic lipid compartment or (2)
the transcellular path through the discontinuous polar (hydro-
philic) environment of the corneocyte compartment which is
interspaced by the hydrophobic lipid bilayers (15). Although
strongly lipophilic substances may readily permeate through the
SC (intercellular route), they partition poorly into the hydrophilic
viable epidermis beneath, which represents another barrier to
delivery. This means that active drugs must exhibit balanced
physiochemical properties (e.g. solubility in lipids and water for
instance) to partition into and permeate across the physio-
chemically different skin compartments to reach their target
site. Small, predominantly lipophilic molecules with some hydro-
philic properties can pass through the skin by simple diffusion
(16). For other types of molecules, achieving sufficient bioavail-
ability at the target site within the skin requires assistance. A
third, indirect, route of drug absorption involves the piloseba-
ceous unit (12). In this case, the hair follicle acts as a reservoir
from which drug is slowly released over time. The most com-
mon route of drug absorption is the intercellular path through
the SC, followed by the follicular path. Through careful design,
vehicles can be designed to disrupt the barriers presented along
these paths to facilitate the absorption of the drug (12). The
amount of active drug that ultimately passes through the skin
and enters systemic circulation is generally very low. In the case
of TCSs the amount that is systemically absorbed is typically
less than 5% of the applied drug (17).
The anatomical site of drug application is an important con-
sideration. Anatomical variations in the density of hair follicles,
sebum production, sweat, moisture levels and SC thickness all
affect absorption (18). The number of corneocyte layers making
up the SC varies from 6 on the genitals to 86 on the heel in
healthy adults, significantly affecting the permeation barrier and
consequently drug bioavailability (19). This is reflected in the
range of SC thickness from 66 microns on the eyelid to 660
microns on the sole of the foot (20). As a result the greatest
absorption of TCS is on the eyelid, genitals, the rest of the face,
and the flexures, and these are therefore at greater risk of local
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Figure 1. The structure of the skin barrier in healthy and AD skin. The vehicle and the paths of drug delivery are illustrated in red. The first path (1) is the inter-
cellular route around the corneocytes. The second path (2) is the transcellular path, which passes through the hydrophilic corneocytes and the lipophilic lipid
lamellae. The path of drug delivery is shorter and less challenging in the skin of AD patients.
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adverse side effects (21,22). In patients with AD the drug perme-
ability barrier is diminished due to pathological degradation of
the skin barrier, meaning that patients with AD are, in general,
at greater risk of systemic drug absorption depending on the
severity of the condition (23).
Vehicle formulation
It is difficult to appreciate the skill involved in formulating and
creating topical vehicles when reviewing a list of excipients. As
an example of this unseen complexity, Stoughton revealed that
generic formulations of triamcinolone acetonide and betametha-
sone valerate preparations were significantly less potent than
the original trade name preparations (24). In this case, triamci-
nolone acetonide cream from the original manufacturer at three
different strengths, 0.025%, 0.1% and 0.5%, exhibited similar
potency, with vasoconstriction scores of 54, 56, and 54, respect-
ively (a higher score indicates higher vasoconstrictor activity
and therefore greater potency). All potencies, including 0.025%,
displayed greater potency than 5 generic 0.1% triamcinolone
acetonide formulations from other manufacturers, which dis-
played vasoconstriction scores ranging from 21 to 41.
No single approach is suited to all drugs and uses, and so a
bespoke approach is required based upon the physiochemical
properties of the drug (12,13). Some of the common ingredients
of vehicles and their functions are provided in Table 1 for refer-
ence (25). Broadly, to enhance drug delivery, vehicles can be
designed to alter the solubility of the drug, include chemical or
physical carriers or carrier systems and/or occlude the skin (oint-
ments or films). Physical occlusion increases the hydration of
the skin and markedly increases skin penetration of applied sub-
stances. This phenomenon underpins the usefulness of patch
testing to readily assess skin responses to irritants and allergens.
Hydrocarbon ointments provide reasonable skin occlusion and
so aid drug delivery (26).
The solubility of the drug is manipulated to improve parti-
tioning from the vehicle into the SC. Malzfeldt et al.
demonstrated that the solution capacity of the vehicle can
greatly affect the clinical efficacy of betamethasone-17-benzoate
preparations despite the drug concentrations being the same
(27). In this case, betamethasone-17-benzoate (0.0056%) deliv-
ered in a vehicle as a suspension (i.e. having low solubility in or
affinity for the vehicle) yielded 80% clearance of dermatoses
compared with only 40% clearance in a solution type vehicle
(wherein the drug was 50 more soluble).
The metamorphosis of the vehicle following application can
have a profound effect of drug solubility and partitioning (18).
Upon application, volatile solvents, such as water, alcohol, and
propellants (used in foams and sprays) begin to evaporate and
change the solubility of the drug. The excipients remaining on
the skin surface following the evaporation of these volatiles is
often referred to as the secondary formulation. In sophisticated
formulations, this is used to force partitioning of the drug into
the SC. In this way, aqueous-ethanolic quick-break foam formu-
lations of betamethasone valerate can yield greater bioavailabil-
ity than cream formulations due to the rapid evaporation of
ethanol upon application (28). Note that the bioavailability of
the foam formulation was comparable to the ointment formula-
tion; the semi-occlusive property of ointments appears to
enhance drug delivery compared to creams. In another example,
however, calcipotriene and betamethasone dipropionate in an
aerosol foam delivered greater bioavailability compared to an
ointment vehicle (29). This nicely demonstrates that both the
“form” (foam vs. cream vs. ointment) and “composition” (dis-
cussed below) contribute to bioavailability.
To facilitate drug delivery, chemicals that disrupt the struc-
ture of the SC, referred to as penetration enhancers, are used.
Many penetration enhancers, like propylene glycol, are also sol-
vents and so can be used, alone or in combination, to help
facilitate both the partitioning into and the passage through
the SC. However, care must be taken in selecting and using
chemical penetration enhancers. Overzealous use can lead to
unwarranted systemic absorption of the drug and skin irritation.
Propylene glycol is a commonly used solvent and penetration
Table 1. Examples of common vehicle ingredients and their properties,.
Ingredient type Rolea Examples Effects on the skinb
Lipids and hydrocarbons
(oils and waxes)
Main structure forming materials
for semi-solid dosage forms
White soft paraffin/petrolatum, liquid
paraffin, lanolin, beeswax, carnauba
wax, cetyl alcohol, isohexadecane
Occlusive and skin conditioning (skin soothing
and softening agents)
Thickening/gelling agents Main structure-forming materials
for gels and viscosity-
enhancing agents for creams
and lotions
Carbomer, methyl cellulose, guar gum,
gelatin, sodium alginate
–
Silicones Lubricant and film-forming agent Dimethicone Occlusive and skin protecting
Humectants (polyols) Promotes water retention in the
vehicle system and skin
Glycerol, sorbitol Moisturizing, skin protecting, skin barrier
stabilizing
Emulsifiers Surfactants use to make
emulsions of water and lipids
Glycerol monostearate, cetostearyl
alcohol, cetyl palmitate, polysorbate
60, sorbitan monostearate
Skin conditioning. Harsh surfactants can have
deleterious effects by dissolving lipids and
irritating the skin
Solvents Used to dissolve or
disperse the drug
Water, propylene glycol, hexylene glycol,
oleyl alcohol, mineral oil/
liquid paraffin
Various, as described for other types
Penetration enhancers Propylene glycol, oleic acid, isopropyl
myristate, ethanol
Disrupt the skin barrier to enhance drug
delivery. Can be irritating in high
concentrations
pH regulators Maintain optimum pH for drug/
delivery system
Citric acid, lactic acid, phosphoric acid,
sodium hydroxide
Products with high buffering capacity can alter
skin surface pH positively and negatively
Antioxidants Help stabilize the active drug Butylated hydroxyanisole,
butylated hydroxytoluene
Oxidative stress within the SC is associated
with barrier disruption and inflammation
Preservatives Prevents microbial contamination
of the product
Parabens, benzyl alcohol, chlorocresol,
ethylene diamine tetraacetate
These are added to protect the product rather
than exert an antiseptic effect on the skin
aMany ingredients display multiple properties and effects on the skin.
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enhancer, which is thought to integrate into the hydrophilic
regions of the packed SC lipids and increase the solubility of
this domain for the permeant (15), yet at high concentrations
(above 10%) can irritate the skin (12,30). In contrast, long chain
fatty acids like oleic acid insert between the hydrophobic lipid
tails to increase the fluidity of the lamellar bilayers. Surfactants
and detergents also act as penetration enhancers by solubilizing
the SC lipids (31). With respect to the treatment of patients with
AD, however, there is a more fundamental issue concerning the
integrity of the skin barrier. Abrogation of this defensive barrier,
which leaves the skin exposed to irritants and allergens, is an
important factor in the development and exacerbation of AD
(3). Penetration enhancers by nature damage this barrier, and so
a careful tradeoff must be made between delivering a thera-
peutic drug dose and protecting the integrity of this barrier.
The cutaneous inflammation experienced by patients with AD
promotes hypersensitivity and also suppresses skin barrier func-
tion (8). The effective delivery of anti-inflammatory drugs,
including corticosteroids and calcineurin inhibitors, using pene-
tration enhancers can therefore bring about a net improvement
in skin barrier function when used in the right way to inhibit
inflammation (32,33). In an added complication, the prolonged
use of TCSs after resolution of inflammation prevents full recov-
ery of the skin barrier owing to suppressive effects of the drug
on skin barrier genes, which are linked to the widely established
atrophic effects of this therapy (34,35).
Beyond chemical penetration enhancers, other formulation
technologies can help deliver drugs to the target site within the
skin and in a controlled way. Some examples include nanopar-
ticles, liposomes, noisomes, transferosomes, ethosomes, and
microemulsions. Nanoparticles appear to concentrate drug deliv-
ery to the epidermis and limit onward transit (36). Liposomes
are purported to slowly release the drug to achieve sustained
delivery over longer periods of time, while also minimizing sys-
temic absorption (37). In addition to augmenting the delivery of
active drugs microemulsions display skin barrier protective and
moisturizing properties (38).
The application of these strategies to improve drug delivery
has led to the development of TCSs with wide-ranging clinical
effects, even where the active corticosteroid and concentration
in the vehicle are the same. Betamethasone dipropionate, for
example, is represented in 4 potency classes from mid-strength
to super-potent, at the same drug concentration of 0.05%
(Table 2) (12). This is achieved in part by augmenting the
vehicle formulation using solvents and penetration enhancers,
principally including propylene glycol (39,40). Although oint-
ments generally appear to perform better than creams and
lotions, the higher potency of augmented betamethasone dipro-
pionate 0.05% cream over betamethasone dipropionate 0.05%
ointment is a good example of how this assumption can be
misleading (18). Moreover, the form of vehicle chosen should be
based upon more than drug delivery.
The properties of vehicles
Topical vehicles take a number of different forms, which are
summarized in Table 3 (42). Beyond the physiochemical require-
ments of the active drug, clinical need and cosmetic acceptabil-
ity play important roles. For the treatment of AD, vehicle forms
with a high content of lipids and skin conditioning agents (also
known as emollient ingredients) are optimal owing to their abil-
ity to soften, soothe, and protect the skin (41). Adherence to
topical therapies is notoriously low (43), and so the choice of
product should be guided first and foremost by the preferences
of the patient, with regard to cosmetic acceptability, to ensure
it is used in necessary quantities (44). Poor adherence to topical
therapies prevent patients from achieving control of their skin
dysfunction/disease (45).
Creating different dosage forms requires a wide range of dif-
ferent ingredients referred to as excipients in pharmaceutical
formulation. Excipients typically make up more than 90% of a
finished pharmaceutical product, and are often considered
‘inactive’ in terms of their effects on the skin (13). As alluded to
above, however, the ingredients of vehicles are shared with
another important class of topical preparation: emollients.
Emollients are skin moisturizers that are based upon ingredients
with ‘skin conditioning’ and ‘occlusive’ properties (46,47). Where
these ingredients are seen as excipients in vehicles, they are
considered active compounds in emollients due to the diverse
benefits they impart on the skin (Table 1). Therefore, it is
important to recognize that rather than being inert carrier sys-
tems for drugs, emollient vehicles possess therapeutic potential
in their own right. Indeed, many vehicles are marketed as emol-
lients, so it should be clear there is no distinction between
the two.
The therapeutic mechanism of action of emollients
(used alone or as vehicles)
Topical emollients (henceforth meaning emollients used alone
and emollients used as vehicles), exhibit therapeutic effects in
AD patients beyond that expected of simple moisturizers (48).
Although a new generation of skin barrier repair emollients aim
to directly correct skin barrier dysfunction by enhancing the
expression of key skin barrier genes (49) or by replacing the
essential skin lipids required for optimal function (50), the focus
here is on the traditional mechanisms currently common to top-
ical emollients.
Artificial restoration of the skin barrier
Emollients are typically based around long chain hydrocarbon
mixtures such as petrolatum (soft paraffin) and mineral oil
(liquid paraffin). When applied to the skin these hydrocarbons
form an occlusive layer over the surface of the skin (26).
Rather than simply sitting on the top, they appear to enter
the defective SC matrices and replace the intercellular lipid
bilayers. In doing so, permeability barrier function is transi-
ently restored (Figure 2). Pure ointments have been shown to
transiently reduce transepidermal water loss by as much as
50%. By trapping water underneath this artificial barrier, the
SC is rehydrated and softened. The effect is transient, lasting
at most 8 h, necessitating frequent application (51,52). The
semipermeable barrier formed by petrolatum creates an opti-
mum environment for rapid skin barrier repair following dam-
age (53). Complete occlusion of the skin with an
impermeable barrier inhibits the repair response, whereas dry
skin is prone to excessive inflammation leading to tissue
hyperplasia. Rather than being a purely physical effect, recent
evidence suggests that skin occlusion and skin treatment with
a simple paraffin-based cream independently trigger molecular
changes that drive the repair response (54). These changes
include increased expression of genes encoding skin barrier
structural components (filaggrin [FLG] and loricrin [LOR]) and
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innate immune system mediators (IL-1b, IL-6, and IL-8). IL-1b,
IL-6 and IL-8 are important pro-inflammatory cytokines
released in response to skin barrier disruption that help
orchestrate the repair response. IL-17 and IL-22 are inducers
of antimicrobial peptide expression. The increased expression
of IL-17 and IL-22 was accompanied by increased expression
of the antimicrobial peptides S100A7, S100A8, S100A9,
S100A12, lipocalin 2, LL37, PI3, and chemokine ligand 20. An
earlier study by Buraczewska et al. support these findings by
demonstrating that the long-term treatment of skin with two
different moisturizers differentially affected the expression of
genes involved in keratinocyte differentiation and desquam-
ation (55). The hydrocarbon-rich cream (20% isohexadecane
and 20% paraffin) increased gene expression of involucrin,
transglutaminase 1, kallikrein 5, and kallikrein 7, whereas the
comparator cream (with low levels of hydrocarbons) inhibited
expression of cyclin-dependent kinase inhibitor 1A.
Patients with AD exhibit weakened physical and antimicro-
bial defenses supporting the therapeutic benefits of this novel
mechanism of action of paraffin-based emollients (3,9).
Suppression of these skin barrier functions is driven by the Th2-
skewed inflammatory state of AD skin, characterized by a cyto-
kine milieu comprising IL-4, IL-5, and IL-13. A clear inhibitory
effect of petrolatum on Th2 inflammatory responses was not
observed by Czarnowicki et al.; however, a reduction in inflam-
matory cell infiltrates was observed in petrolatum treated skin
(54). Petrolatum has also been found to inhibit the synthesis of
prostaglandins in the skin (56). Prostaglandins are important
mediators of tissue inflammation in patients with AD. Further
back, in 1975, Tree and Marks first uncovered the antimitotic
effects of petrolatum on the skin and raised the therapeutic
implications this could have for topical placebos (7).
How exactly simple paraffin-based creams elicit these
molecular changes independent of occlusion/hydration is
Table 2. Topical corticosteroid potencies.
Class Generic name (brand name) Dosage form Strength (%)
Class I (super potent) Betamethasone dipropionate (Diprolene) Ointment 0.05
Clobetasol propionate (Temovate, Dermoxin) Ointment, cream 0.05
Diflorasone diacetate (Fluorone, Psorcon) Ointment 0.05
Halobetasol propionate (Ultravate) Ointment, cream 0.05
Class II (very potent) Amcinonide (Cyclocort) Ointment 0.1
Betamethasone dipropionate (Diprolene, Diprosone) Ointment, cream, foam, solution 0.05
Desoximetasone (Topicort) Ointment, cream 0.25
Desoximetasone (Ibaril) Gel 0.05
Diflorasone diacetate (Florone, Maxiflor) Ointment 0.05
Fluocinonide (Lidex) Ointment, cream, gel 0.05
Halcinonide (Halog) Ointment, cream 0.1
Mometasone furoate (Elocon, Ecural) Ointment 0.1
Triamcinolone acetonide (Kenalog) Ointment, cream 0.5
Class III (potent) Amcinonide (Cyclocort) Cream, lotion 0.1
Betamethasone valerate, (Valisone) Ointment 0.01
Diflorasone diacetate (Florone, Maxiflor) Cream 0.05
Fluticasone propionate (Cutivate) Ointment 0.005
Fluocortolone (Ultralan) Cream 0.25
Fluocinonide (Lidex E cream, Topsyn) Cream 0.05
Halcinonide (Halog) Ointment 0.1
Triamcinolone acetonide (Aristocort A) Ointment 0.1
Triamcinolone acetonide (Aristocort-HP) Cream 0.5
Class IV (moderately potent) Betamethasone valerate (Valisone, Luxiq) Lotion 0.01
Desoximetasone (Topicort-LP) Cream, gel 0.05
Fluocinolone acetonide (Synalar-HP) Cream 0.2
Fluocinolone acetonide (Synalar) Ointment 0.025
Flurandrenolide (Cordran) Ointment 0.05
Halcinonide (Halog) Cream 0.025
Hydrocortisone valerate (Westcort) Ointment 0.2
Mometasone furoate (Elocon, Ecural) Cream 0.1
Triamcinolone acetonide (Kenalog) Ointment 0.1
Class V (moderate) Betamethasone dipropionate (Diprosone) Lotion 0.05
Betamethasone valerate (Valisone) Cream 0.01
Fluocinolone acetonide (Synalar) Cream 0.025
Fluocinolone acetonide (Dermasmoothe/FS) Oil 0.01
Flurandrenolide (Cordran) Cream 0.05
Fluticasone propionate (Cutivate) Cream 0.05
Hydrocortisone butyrate (Locoid) Cream 0.1
Hydrocortisone valerate (Westcort) Cream 0.2
Triamcinolone acetonide (Kenalog) Lotion 0.1
Class VI (mild) Alclometasone dipropionate (Aclovate) Ointment, cream 0.05
Betamethasone valerate (Valisone) Lotion 0.05
Desonide (Desowen, Tridesilon) Cream 0.05
Fluocinolone acetonide (Synalar) Cream, solution 0.01
Prednicarbate (Dermatop) Cream 0.1
Triamcinolone acetonide (Aristocort) Cream 0.1
Class VII (very mild) Dexamethasone (Decadron phosphate) Cream 0.1
Hydrocortisone (Hytone, others) Various 0.5, 1, 2.5
Adapted from Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids, J Am Acad Dermatol, 2006;54(1):1–15, with permission
from Elsevier (21).
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unclear. One possible explanation is the persistence of trace
amounts of aromatic hydrocarbons from the purification of par-
affin (54). Aromatic hydrocarbons trigger IL-17 and IL-22 medi-
ated responses via the aryl hydrocarbon receptor (AHR), and it
is now thought these underpin the therapeutic effects of coal
tar in the treatment of psoriasis (57,58).
Replenishment of skin moisturizers
Although pure ointments display good occlusion, emollient
creams and gels exhibit limited occlusive effects due to the
reduction in waxes and oils (52). In these cases, humectants are
often added to improve their moisturizing effects. When applied
to the skin they help replenish the low levels of NMF associated
Table 3. Common vehicle forms.
Form Descriptiona Clinical use and acceptability Comments
Ointment A suspension or emulsion semisolid dosage
form that contains <20% water and
volatiles and >50% of hydrocarbons,
waxes, or polyols
Suited to palmoplantar skin and
infiltrated, lichenified lesions
Often comprising >80% petrolatum, they display
superior occlusive and emollient properties
compared to other forms. However, the greasy
nature of ointments makes them less acceptable
to patients
Cream An emulsion semisolid dosage form that
contains >20% water and volatiles and/
or <50% of hydrocarbons, waxes, or
polyethylene glycols. Emulsifiers are
used to create and stabilize the
emulsion between the phases (18)
Acute and subacute lesions The active drug is dispersed between the water and
oil phases depending on its partition coefficient.
Being easy to apply, these provide a good
compromise between emollient efficacy and
patient compliance
Gel A semisolid dosage form that contains a
gelling agent to provide stiffness to a
solution or colloidal dispersion
Suitable for all lesions An easy to apply alternative to creams; however,
aqueous (monophasic) gels lack emollient
properties. To improve the suitability of gel
vehicles for AD treatments, emulsified gels
(emugels) have been developed (dual phase
systems of lipid dispersed in water)
Lotion An emulsion liquid dosage form with
>50% water and volatiles
Acute and subacute lesions. Not
generally suitable for use on very
dry skin
Easily applied over large areas of skin, but do not
display the benefits of lipid-rich cream and
ointment vehicles (41)
Foam Multiphase suspension containing a
propellant stored under pressure and
forming a foam upon release that
quickly breaks down on the skin
Suited to inflamed or sensitive areas
because of the reduced need to
rub them into the skin
Particularly suited to hairy areas of skin. Typically
have limited occlusive properties
aDescriptions taken from Buhse et al., 2005 (42).
Optimal skin barrier with
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Figure 2. Mechanism of action of emollients. A healthy skin barrier (a) comprises two main structural compartments; including the corneocytes (boxes) and the
extracellular lipid lamellae (shading around the boxes). The corneocytes contain natural moisturizing factors (NMF) that bind to water and keep the stratum cor-
neum hydrated. The lipid lamellae are a highly ordered matrix of lipids that prevents the movement of water between the corneocytes. Together these compart-
ments form an effective permeability barrier to water and external irritants and allergens. In AD skin (b) there is a deficiency in NMF and a lipid abnormality that
disrupts the permeability barrier, leading to elevated transepidermal water loss (TEWL) and increased susceptibility to irritants and allergens. Occlusive emollients
(c) coat the skin to form a transient semi-occlusive barrier. This nonphysiologic barrier artificially restores barrier function and traps water in the SC to rehydrate
the skin. Humectants (d) are added to emollients to replace the lost NMFs and increase the water-holding capacity of the skin.
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with AD (Figure 2) (59). Polyols are particularly effective humec-
tants, with glycerin (synonyms glycerol and glycerin) commonly
found in emollient creams and lotions (46). Other humectants
that can be found in emollients include pyrrolidine carboxylic
acid, lactic acid, and urea, which are constituents of NMF in the
skin. In very dry environments, humectants exhibit reduced effi-
cacy. Under such circumstances, glycerol and urea have been
found to soften the skin by inhibiting the transition of the inter-
cellular lamellar lipids from liquid to solid crystal phase. This
skin conditioning property is also associated with increased per-
meability, meaning humectants like glycerol and urea can be
utilized in vehicles as penetration enhancers (60,61).
Beyond skin moisturization, humectants appear to help accel-
erate skin barrier repair. Although some of this effect can be
attributed to their humectant activity, they also display distinct
molecular effects. Glycerol, for instance, significantly accelerates
skin barrier recovery when applied to the skin following disrup-
tion (62,63). Urea, but not glycerol, appears to strengthen the
skin barrier and protect against surfactant induced irritation
(64,65). This effect has been attributed to the ability of urea to
stimulate the expression of keratinocyte differentiation-depend-
ent genes such as the one encoding the structural protein filag-
grin (49,66). Filaggrin gene defects in particular are a strong
predisposing factor for AD (67). Lactic acid promotes the expres-
sion of genes involved in ceramide synthesis (68). As mentioned
above, the skin of patients with AD is characterized by abnormal
differentiation, which predominantly includes reduced expres-
sion of filaggrin, and altered lipid metabolism leading to
reduced ceramide levels (5,51).
Altering skin surface properties
An often-overlooked aspect of topical products is how they
affect the physiochemical properties of the skin surface. The pH
of the skin surface is a particularly important property with rele-
vance in the pathophysiology of AD (69). Healthy skin exhibits
an acidic surface of pH 4.5 to 5.0 that restricts corneocyte shed-
ding (desquamation), promotes lipid processing, and prevents
the growth of pathogenic bacteria. In AD, skin surface pH
increases, reaching as high as pH 7.0 at acute skin lesions. As a
result, the SC becomes thinner as desquamation outstrips the
formation of new corneocytes, lipid processing is inhibited, and
the skin microbiome changes markedly. In particular, the skin
environment becomes more conducive to S. aureus colonization.
More than 90% of AD lesions are colonized by this bacterium,
the extent of which closely associates with severity of the condi-
tion (11). In animal models, the maintenance of an acidic SC can
prevent the emergence of AD, highlighting the potential benefit
of manipulating skin pH in humans (70). Topical leave-on prod-
ucts can be used to manipulate the pH of the skin surface.
Preparations that lower the pH of the skin appear to enhance
skin barrier structure and alter the skin microbiome (71).
Unfortunately, however, the majority of emollients appear to
exhibit a relatively high pH that could contribute to the abnor-
mal skin barrier homeostasis seen in patients with AD (72).
Clinical efficacy of emollients (used alone or
as vehicles)
The evidence presented above suggests that far from being sim-
ple moisturizers, emollients help correct two key pathophysio-
logical processes underpinning AD by promoting skin barrier
restoration and innate immune responses at a molecular level.
Clinically there is robust evidence that the regular use of emol-
lients reduces the severity of AD; however, the level of reduc-
tion is small and of questionable clinical significance (48,73).
Patients agree that using emollients is more effective at reduc-
ing the severity of AD overall, and specifically at reducing itch,
compared with no treatment. When used as a maintenance
therapy following flare resolution, emollients significantly pro-
long the period before the next flare, reducing the risk of a new
flare by 3.74 compared with no treatment (74,75). The use of
an emollient was also associated with a reduced need (by half)
for TCSs as a rescue therapy. When emollients are used in com-
bination with TCSs, clinical efficacy was significantly improved
and the risk of new flares reduced by 2.38 compared with TCS
treatment alone.
The benefits of using emollients are highly dependent on
the frequency of application (51), in agreement with the transi-
ent effects of occlusive ingredients. Although there is very lim-
ited evidence comparing emollients with other emollients, it is
clear that not all emollients are equal. Some emollients, like
Aqueous Cream BP, containing harsh surfactants, damage the
skin barrier and consequently increase the risk of cutaneous
adverse reactions (76). Glycerol-based emollients in general
exhibit significantly greater efficacy at treating skin dryness
compared to emollients without glycerol, and concordantly
demonstrate greater overall efficacy in treating AD (48). Caution
is required in generalizing the benefits of emollients based on a
single perceived active ingredient, however, as the interaction
between active moisturizing agents and other excipients is
known to substantially affect overall efficacy, much like vehicle
design appreciably affects drug delivery and response (77,78).
Unfortunately, few studies directly compare the efficacy of emol-
lients at reducing the severity of AD or improving the control of
the condition, especially considering the wide array of emollient
formulations available. In a recent example, Akerstrom et al. dir-
ectly compared a urea-containing emollient to a bland emollient
without humectants in a randomized, controlled flare preven-
tion trial (79). A greater than two-fold difference in the propen-
sity to new flares of AD was found between the treatment
groups. Together these findings on emollients support a wider
role for emollients as important adjuvants to topical active
therapies such as TCSs, rather than stand-alone therapies.
Vehicles display heterogenous efficacy in AD clinical trials
It is common practice to compare new topical pharmaceutical
treatments to their vehicles or a similar topical control in
randomized controlled trials (RCTs). Often the term placebo is
used, however, this is incorrect and misleading given that
vehicles/topical controls are often essentially emollients with
inherent therapeutic effects (80). Very rarely would no treatment
be used as a control due to the ethical implications of withhold-
ing treatment. Recent systematic reviews have compiled and
compared the clinical responses to drug treatments for AD,
including corticosteroids and calcineurin inhibitors (73,81,82).
What is striking about these studies is the often marked
response to the control treatment. Table 4 summarizes some of
these studies, providing the relative responses to the pharma-
ceutical drug treatment and the vehicle control. Following the
strategy of Fishbein et al., responders were defined as patients
displaying either a ‘good response’ as defined by the study
protocol, a 50% reduction in AD severity, or AD rated as cleared
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Table 4. Vehicle effects in randomized controlled trials of AD therapies.
Study Treatmenta Control
Number
of patients
(treatment,
control) Population
Frequency of
application
Duration of
treatment
(days)
Response to
treatmentb
Response to
controlb
Ratio of
response
Topical corticosteroid ointmentsc
Udompataikul and Limpa-o-
vart, 2012 (83)
Hydrocortisone
1% ointment (VII)
Dexapanthenol
5% ointment
26, 26 Mild-moderate BID 28 87 87 1.00
Topical corticosteroid creamsc
Sudilovsky et al., 1981 (84) Halcinonide 0.10% cream (II) Vehicle, cream 58, 58 Not reported BID 21 57 17 3.35
Sugarman and Parish,
2009 (85)
Fluticasone propionate 0.05%
cream (III)
Emollient cream containing
a ceramide dominant
mixture of physiologic lipids
59, 53 Moderate-severe BID 28 44 36 1.22
Abramovitis and Oquendo,
2010 (86)
Hydrocortisoine butyrate 0.1%
lipocream (V)
Vehicle, emollient cream 131, 133 Mild-moderate BID 21–29 63 28 2.25
Stalder et al., 1994 (87) Desonide 0.1% cream (III) Placebo, cream 18, 21 Not reported QD 7 57 14 4.07
Rauschkolb et al., 1981 (88) Halcinonide 0.025% cream (IV) Placebo, unspecified cream 79, 79 Not reported TID 14 81 51 1.59
Luger et al., 2001 (89) Betamethasone valerate
1% cream (III)
Vehicle, cream 42, 43 Moderate-severe BID 21 88 16 5.50
Subtotals 65 27 2.99
Topical corticosteroid lotionsc
Matheson et al. 2008 (90) Hydrocortisone butyrate
0.1% lotion (V)
Vehicle, lotion 139, 145 Mild-moderate BID 28 49 24 2.04
Eichenfield and Miller, 2006
study 1 (91)
Fluticasone propionate 0.05%
lotion (V)
Vehicle, lotion 110, 110 Moderate-severe QD 28 75 32 2.34
Eichenfield and Miller, 2006
study 2 (91)
Fluticasone propionate 0.05%
lotion (V)
Vehicle, lotion 111, 107 Moderate-severe QD 28 66 27 2.44
Subtotals 63 28 2.27
Topical corticosteroid gelsc
Hebert et al., 2007 (92) Desonide 0.05% gel (VI) Vehicle, hydrogel 425, 157 Mild-moderate BID 28 39 11 3.54
Topical calcineurin inhibitor creamsd
Luger et al., 2001 (89) Pimecrolimus 1% cream Vehicle, cream 45, 43 Moderate-severe BID 21 53 16 3.31
Eichenfield et al., 2002 (93) Pimecrolimus 1% cream Vehicle, cream 267, 136 Mild-moderate BID 28 31 11 3.65
Kapp et al. 2002 (94) Pimecrolimus 1% cream Vehicle, cream 204, 47 Mild-severe BID 21 55 39 1.41
Ho et al., 2003 (95) Pimecrolimus 1% cream Vehicle, cream 123, 63 Mild-moderate BID 21 44 17 2.47
Subtotals 46 21 2.71
Topical calcineurin inhibitor ointmentsd
Boguniewicz et al. 1998 (96) Tacrolimus 0.03% ointment Vehicle, ointment 43, 44 Moderate-severe BID 21 58 27 2.15
Boguniewicz et al. 1998 (96) Tacrolimus 0.1% ointment Vehicle, ointment 49, 44 Moderate-severe BID 21 43 27 1.59
Subtotals 51 27 1.87
PDE4 inhibitors
Paller et al. 2016
study 1 (97)
Crisaborole 2% ointment Vehicle, ointment 503, 256 Mild-moderate BID 28 52 41 1.27
Paller et al. 2016
study 2 (97)
Crisaborole 2% ointment Vehicle, ointment 513, 250 Mild-moderate BID 28 49 30 1.63
Subtotals 51 36 1.45
aTopical corticosteroid potency class in brackets.
bPercentage of patients achieving clear or almost clear.
cSee systematic review by Fishbein et al., 2019 (81).
dSee systematic review by El-Bataway et al., 2009 (82).
BID: twice daily; OD: once daily.
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or controlled in order to overcome the reporting differences
(81). This is an important limitation, and extreme caution should
be taken in interpreting the responses quoted due to the meth-
odological differences between the studies. On average, 65% of
patients responded to treatment with various corticosteroid
preparations administered for between 1 and 4weeks compared
with 32% for the control group. The response to the vehicle
was heterogenous, ranging from 11% to 87%. This heterogen-
eity of response could not be explained by the age of partici-
pants or the duration of treatment. One contributing factor
could be the severity of the AD. A smaller difference between
the efficacy of a vehicle and TCS would be expected in mild AD
relative to severe AD.
A crude observation is the overall response associated with
each form of vehicle. Lotion vehicles were associated with a
response rate of 28%, compared with 27% for creams, and 87%
for the only ointment preparation tested. The lowest response
of 11% was reported for a hydrogel vehicle, containing the
humectant glycerin and no emollient ingredients (92). Notably,
this study reported one of the largest separations in the effect
of the pharmaceutical active preparation (desonide, 0.05%,
potency class IV) and vehicle despite a moderate response to
the former. It is tempting to postulate that the absence of a
strong vehicle effect revealed a more pronounced effect of the
active drug. In a subsequent RCT, desonide 0.05% gel was com-
pared with desonide 0.05% ointment (98). The ointment prepar-
ation was associated with a greater reduction in the severity of
AD compared with the gel. It is not clear whether this difference
stems from an enhanced therapeutic effect of the vehicle,
enhanced drug delivery. or a combination of both. A similar
situation was reported by Stalder et al., where a large separation
in the effects of desonide 0.1% cream (potency class III) was
observed compared with a vehicle lacking in occlusive and
emollient ingredients (87). Just 14% of patients responded to
the control, whereas 57% responded to the pharmaceutical des-
onide preparation.
At the other end of the spectrum, Sugarman and Parish
demonstrated equivalent efficacy between a complex emollient
containing a ceramide dominant mixture of physiologic lipids
and fluticasone propionate 0.05% cream (potency class III) (85).
Similarly, Udompataikul and Limpa-O-Vart found a comparable
therapeutic response to hydrocortisone 1% ointment (potency
class VII) and a vehicle ointment containing the cosmetic skin
conditioning ingredient dexpanthenol (83). Parneix-Spake et al.
investigated the effects of clobetasol butyrate 0.05% cream
compared with its vehicle and hydrocortisone 1% cream on
nickel-induced contact dermatitis (patches containing nickel
were applied to induce dermatitis prior to the 7-day treatment
period) (99). Although clobetasol butyrate displayed the greatest
therapeutic effect, the vehicle alone displayed greater efficacy at
reducing dermatitis and correcting skin barrier dysfunction than
either no treatment or treatment with hydrocortisone 1% cream.
The positive effects of the vehicle have been attributed to its
high concentration of the humectant glycerol. This is also a
good example of where the vehicle for a pharmaceutical prod-
uct is also marketed in its own right as an emollient treatment
for dry skin.
Looking to other anti-inflammatory treatment for AD, RCTs of
calcineurin inhibitors tacrolimus and pimecrolimus appear to
show a stronger vehicle effect for the ointment base of the for-
mer compared to the cream base of the latter (82). The strength
of this response appears to reduce the perceived efficacy of the
more potent tacrolimus compared with pimecrolimus. A particu-
larly strong vehicle effect was also reported in the RCTs for the
newly developed phosphodiesterase 4 inhibitor crisaborole in
patients with mild to moderate AD, which appears to conceal
the otherwise strong response to the drug treatment (97). These
observations beg the question of whether drug effects always
augment vehicle effects (the assumption that underpins the
vehicle control design) or whether they in fact mask them by
reducing the therapeutic window.
Vehicles and flare prevention
The proactive use of topical pharmaceutical treatments at
reduced application frequencies over long periods of time has
been shown to reduce the risk of flares and improve the long-
term control of AD (100). As mentioned above, emollients dis-
play significant potential as flare reduction therapies in their
own right (48). This suggests that the vehicle effect may be
stronger in flare prevention studies conducted over longer peri-
ods of time. In a study by Siegfried et al., significantly more par-
ticipants receiving proactive treatment with pimecrolimus cream
were flare free at 6months (52%) compared with those receiv-
ing vehicle (34%) (101). Similar findings have been reported in
other studies (94,102,103), suggesting a 1.5 lower risk of flares
in the interventional group compared with the vehicle group
overall. Although there is a clear distinction between the vehicle
plus active drug and the vehicle alone in each case, the differ-
ence in effects is notably smaller than reported in trials of short-
term reactive treatment. In the study by Kapp et al., the
response to treatment was monitored at 3weeks, 6months, and
12months (94). Although pimecrolimus 1% cream displayed sig-
nificantly greater efficacy compared with the vehicle at 3weeks
in this study, the difference in effects was lost after 12months
due to an enhanced response to the vehicle with time. Studies
by Wiren et al. (75) and Weber et al. (74) demonstrate that
emollient treatment alone can significantly reduce the risk of
flares, highlighting the potential for strong vehicle effects in this
type of study.
It is interesting that despite the therapeutic contribution of
some emollients in minimizing the occurrence of flares, an
often-overlooked factor in pharmaceutical product flare preven-
tion trials is the concomitant use of emollients (101). The impact
of this baseline therapy is unclear, and rarely characterized in
RCTs. It begs the question ‘does the concomitant use of emol-
lients simply improve the overall therapeutic effect or does it
mask the effects of the pharmaceutical treatments delivered in
a vehicle?’
The interaction between vehicles and other
topical products
It has become common practice to combine the use of topical
anti-inflammatories in emollient vehicles with separate emollient
products in the treatment of AD. The use of emollient therapy
in addition to TCS is superior to the use of TCS alone (47,104).
Moreover, Lucky et al. first reported that once-daily TCS applica-
tion regimens combined with emollient therapy can be as effi-
cacious as twice-daily TCS application regimens without
emollient therapy (105). This finding has since been replicated
in a number of studies that support a significant steroid-sparing
effect of concomitant emollient therapy by as much as 50%
(106,107). There are two explanations for this effect. The first is
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the therapeutic efficacy of emollients reviewed above. The
second is the interaction between the two treatments leading
to altered drug uptake.
A critical factor here is the persistence of drug in the SC fol-
lowing application. In the case of TCSs, the drug reservoir in the
SC lasts for up to 14 days following application depending on
the vehicle formulation—the length of time it takes to renew
the SC (108). Occlusion of the skin at any point during this time
results in a second dose as the corticosteroid stranded in the SC
is driven into the deeper skin layers (28). Similarly, the applica-
tion of emollients can liberate corticosteroids from this reservoir
and facilitate permeation (96,109,110). The type of emollient
applied, specifically the solvent and penetration-enhancing
properties of the constituent ingredients, is important.
Emollients displaying steroid-sparing effects contain penetration
enhancers such as propylene glycol and butylene glycol (106).
They are commonly added to emollients to improve moisturizer
efficacy, but will indiscriminately increase SC permeability.
Unfortunately, even as there has been interest in investigating
the steroid-sparing effects of new emollients, there has been
very limited attention placed on understanding the interaction
of different emollients on SC drug reservoirs.
Although the interaction between emollients and TCS can
enhance the overall therapeutic effect of a treatment regimen,
there are also concerns that it may reduce corticosteroid
responses by diluting the dose or inhibiting uptake (111).
Barrier preparations are designed to help protect the skin from
potential irritants and allergens, and so could conceivably
impede drug uptake if applied first. A small-scale RCT appears
to have found just this, with the application of emollient 15min
before TCS diminishing the response to the treatment compared
with application of the emollient 15min after the TCS (112,113).
Current guidance for patients and healthcare professionals on
the concomitant use of emollients and topical anti-inflammatory
treatments is varied. Despite a lack of evidence there is a belief
that emollients should be applied with TCS, separated by
‘several’ to 60min, either before or afterwards depending on
the guidance followed (112). The lack of clarity is unhelpful for
patients, and so there is a need to understand the necessity for
combined application, the order of application and the interac-
tions between different TCS formulations and different emol-
lients. Suboptimal combinations have the potential to reduce
treatment responses, or at the other end of the spectrum,
increase the risk of systemic adverse effects due to excessive
drug delivery. It would seem therefore, that both the vehicle
and concomitant emollient use are important determinants of
drug efficacy.
Conclusion
The design of vehicles has a clear and profound effect of the
bioavailability, and consequently the clinical efficacy, of pharma-
ceutical drugs. From this comes the impetus to develop the
most sophisticated vehicles to achieve the maximum thera-
peutic response possible in randomized vehicle-controlled trials.
But what if that pursuit actually reduced the chances of finding
a significant therapeutic response because of the effects of the
vehicle itself?
The same technology that improves drug delivery and
response is used to enhance the moisturizer efficacy of emol-
lients. Due to the inherently defective skin barrier in AD
patients, emollient vehicles with moisturizing effects are
therapeutically advantageous on multiple levels. They both
facilitate drug delivery and bring about changes in the skin at
the molecular level, which promotes skin barrier repair, enhan-
ces innate defense systems and suppresses inflammation. These
intrinsically multi-functional vehicles therefore exhibit independ-
ent therapeutic effects. The question is ‘do these effects add to
the potential effects of drug treatments or mask them?’
In the absence of robust evidence, it is not possible to deter-
mine whether vehicles do in fact compete with pharmaceutical
drugs to reduce the distinction in the effects between finished
pharmaceutical product and vehicle. Yet vehicles do often dis-
play strong treatment responses compared with drug treat-
ments. It suggests a need to reevaluate the design of RCTs to
quantify the therapeutic effects of sophisticated emollient
vehicles. We must avoid a situation where vehicles are designed
without consideration for the benefits of emollients as this will
ultimately reduce the convenience of use and ultimately patient
adherence to treatment regimens.
Looking beyond the vehicle, emollients used in conjunction
with pharmaceutical drugs display (secondary) vehicle effects
and can modify treatment responses. The interactions between
the drug, its vehicle and the other products applied to the skin
are not fully understood, and yet evidence demonstrates that
such interactions can significantly affect clinical performance.
We must understand these interactions to streamline treatment
regimens and maximize therapeutic responses. Understanding
how to best use TCS and emollients was recently highlighted as
an important issue for patients and healthcare professionals.
Failing to understand this issue could jeopardize treatment
responses in practice and hinder the development of
new therapies.
Given the complexities of the interaction involved, perhaps
the best solution is to take a holistic approach to topical treat-
ment, where emollient and anti-inflammatory drug combina-
tions are co-developed and tested together against the current
standard of topical therapy in clinical practice.
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